Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 260
- Registration Number
- NCT02101788
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 30
- Registration Number
- NCT02097680
- Locations
- 🇧🇪
Ghent University Hospital, Ghent, Belgium
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 90
- Registration Number
- NCT02095184
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT02093351
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT02010021
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
TRial on the Endocrine Activity of Neoadjuvant Degarelix
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 51
- Registration Number
- NCT02005887
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy
🇮🇹Istituto Toscana Tumori, Prato, Italy
🇮🇹Ospedale degli Infermi, Rimini, Italy
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT01999569
- Locations
- 🇺🇸
Women's Institute at Carolinas Medical Center, Charlotte, North Carolina, United States
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 668
- Registration Number
- NCT01958021
- Locations
- 🇺🇸
Texas Oncology Houston Memorial City SC, Houston, Texas, United States
🇺🇸City of Hope National Medical Center SC-5, Duarte, California, United States
🇺🇸Alta Bates Cancer Center Oncology Dept., Berkeley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.